US FDA expands use of Regeneron's cholesterol drug in young children

World
22-03-2023 | 08:06
High views
Share
LBCI
Share
LBCI
Whatsapp
facebook
Twitter
Messenger
telegram
telegram
print
US FDA expands use of Regeneron's cholesterol drug in young children
Whatsapp
facebook
Twitter
Messenger
telegram
telegram
print
0min
US FDA expands use of Regeneron's cholesterol drug in young children

Regeneron Pharmaceuticals Inc (REGN.O) said on Wednesday the US Food and Drug Administration had approved the expanded use of its drug in children aged 5 to 11 to treat an ultra-rare disease that causes high cholesterol levels.

The drug, Evkeeza, is already approved as an additional treatment, along with other lipid-lowering therapies, for patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH).

HoFH is an inherited condition that affects about 1,300 people in the United States.

The expanded approval makes the drug the first to treat kids with the condition who are less than 10 years old.

The list price of the drug varies by patient weight, and is expected to be roughly $450,000 per year on average, Regeneron had said in 2021.

Reuters 
 

US

FDA

Regeneron

Cholesterol

Drug

Download now the LBCI mobile app
To see the latest news, the latest daily programs in Lebanon and the world
Google Play
App Store
We use
cookies
We use cookies to make
your experience on this
website better.
Accept
Learn More